A Phase III, Double-blind, Placebo-controlled, Multicenter Study on the Efficacy of Recombinant Human Antithrombin in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass - Concepedia

Concepedia

Publication | Open Access

A Phase III, Double-blind, Placebo-controlled, Multicenter Study on the Efficacy of Recombinant Human Antithrombin in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

DOI Full Paper Access

119

Citations

22

References

2005

Year

Michael S. Avidan, Jerrold H. Levy, Jens Scholz, Elise Delphin, Peter Rosseel, Michael B. Howie, Irwin Gratz, Charles R. Bush, Nikolaos J. Skubas, Gabriel S. Aldea,

Abstract

Treatment with 75 U/kg rhAT is effective in restoring heparin responsiveness and promoting therapeutic anticoagulation in the majority of heparin-resistant patients. Treating heparin-resistant patients with rhAT may decrease the requirement for heparin and fresh frozen plasma.

References

	Year	Citations

Page 1